skip to Main Content

Università Cattolica del Sacro Cuore, Largo A. Gemelli, n. 8 – 00168 – Rome (Italy)

Dermatologia e Venereologia

• Tipo di impiego Medico Specializzando in Dermatologia e Venereologia

• Principali mansioni e responsabilità • Attività clinica e di ricerca inerente i principali ambiti della dermatologia (dermatologia

infiammatoria, dermatologia oncologica, dermatologia pediatrica)
• Attività dermo-chirurgica oncologica e ricostruttiva

Ha partecipato in qualità di relatore o partecipante a congressi nazionali e internazionali in
ambito dermatologico

Membro della Società Italiana di Dermatologia medica, chirurgica, estetica e delle Malattie
Sessualmente Trasmesse (SIDeMaST)

Autore di pubblicazioni scientifiche su riviste nazionali e internazionali:

[ 2020 ] Baricitinib: therapeutic potential for moderate to severe atopic dermatitis
Calabrese L, Malvaso D, Chiricozzi A, et al. Baricitinib: therapeutic potential for moderate
to severe atopic dermatitis [published online ahead of print, 2020 Aug 14]. Expert Opin
Investig Drugs. 2020;1-10.

[2020] Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis

Suppurativa Patients

Chiricozzi A, Giovanardi G, Garcovich S, et al. Clinical and Ultrasonographic Profile of
Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric
Experience. Acta Derm Venereol. 2020;100(13):adv00172. Published 2020 Jun 11.
[2020] Apremilast for the treatment of hidradenitis suppurativa associated with
psoriatic arthritis
Garcovich S, Giovanardi G, Malvaso D, De Simone C, Peris K. Apremilast for the treatment
of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients:
Case report and review of literature. Medicine (Baltimore). 2020;99(5):e18991.

[2020] COVID-19 occurrence in one secukinumab-treated patient affected by
hidradenitis suppurativa and systemic lupus erythematosus
Giovanardi G, Peris K. COVID-19 occurrence in one secukinumab-treated patient affected
by hidradenitis suppurativa and systemic lupus erythematosus. Int J Dermatol. 2020 Sep
23:10.1111/ijd.15209.

[2020] Prevalence of Neuropathic Pain and Related Characteristics in Hidradenitis
Suppurativa: A Cross-Sectional Study
Garcovich S, Muratori S, Moltrasio C, Buscemi AA, Giovanardi G, Malvaso D, Di Stasio E,
Marzano AV, Peris K. Prevalence of Neuropathic Pain and Related Characteristics in
Hidradenitis Suppurativa: A Cross-Sectional Study. J Clin Med. 2020 Dec 15;9(12):4046.

[2021] Successful Combination of Systemic Agents for the Treatment of Atopic
Dermatitis Resistant to Dupilumab Therapy
Gori N, Chiricozzi A, Malvaso D, D’Urso DF, Caldarola G, De Simone C, Peris K. Successful
Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to
Dupilumab Therapy. Dermatology. 2021 Jan 21:1-7.

[2020] PASH, PAPASH, PsPASH and PASS: the auto inflammatory syndromes of
hidradenitis suppurativa
Garcovich S, Genovese G, Moltrasio C, Malvaso D, Marzano AV. PASH, PAPASH, PsPASH
and PASS: the auto inflammatory syndromes of hidradenitis suppurativa. Clin Dermal
Published 16, Oct 2020

[2021] Flares as dynamic predictive factor of response to adalimumab in
hidradenitis suppurativa, real-life data
Caposiena C, Chiricozzi A, Sechi A, Molinelli E, Venturini M, Candi E, Malvaso D, Peris K,
Patrizi A, Offidani A, Pinton P, Bianchi L (May 2021). Flares as dynamic predictive factor of
response to adalimumab in hidradenitis suppurativa, real-life data. Giornale Italiano di
Dermatologia e Venereologia.